Compare Merck & Co., Inc. (MRK) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs iShares Silver Trust — how do they compare? Merck & Co., Inc. trades at $144.68 (market cap $351.28B), while iShares Silver Trust trades at $54.91 (market cap $29.02B). The key difference: Merck & Co., Inc. is far larger — about 12.1× iShares Silver Trust's market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares Silver Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and iShares Silver Trust for 89 Days on average.
| MRK | SLV | |
|---|---|---|
Market Cap | $351.28B | $29.02B |
Volume | 7,969,665 | 16,510,334 |
Sector | Health | — |
52-Week High | $156.43 | $105.57 |
52-Week Low | $82.49 | $42.40 |
Typical Hold Time | 98 Days | 89 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
SLV trades at $55.06, up 2.3% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported $2.17M net income for 2024 despite zero revenue, with total assets surging to $13.41B from $10M in 2023. Recent news highlights silver price volatility driven by Fed policy expectations and Treasury yields.
The outlook is clouded by bearish technicals and macroeconomic pressures on silver, though low debt and asset growth offer stability. Risks include interest rate sensitivity and industrial demand fluctuations, while institutional sentiment remains cautious amid price declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
